A novel and safe approach for treating cognitive disorders
July 5, 2023Umecrine Cognition presents data at World Parkinson Congress showing positive effects of golexanolone in a preclinical model of Parkinson’s diseaseStockholm, July 5, 2023 – Umecrine Cognition AB today announced that results from a study on a preclinical model of Parkinson’s disease are being...
June 7, 2023Umecrine Cognition presents new preclinical data that elucidates the mechanism-of-action of golexanolone in cholestatic liver diseaseStockholm, June 7, 2023 – Umecrine Cognition AB today announced new results from a preclinical model of cholestasis that elucidate the...
May 17, 2023Notice to attend the Annual General Meeting in Umecrine Cognition ABSTOCKHOLM – May 17, 2023. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.